New tuberculosis (TB) ethics guidance, launched today by the World Health Organization (WHO), aims to help ensure that countries implementing the End TB Strategy adhere to sound ethical standards to protect the rights of all those affected.
23 March 2017 | World Health Organization
Rising rates of superbug tuberculosis (TB) are threatening to derail decades of progress against the contagious disease, experts said on Thursday, and new drugs powerful enough to treat them are few and far between.
23 March 2017 | Hindustan Times
TB Alliance, a non-profit organization dedicated to developing better and faster cures for tuberculosis (TB), today announced a unique collaboration with food and beverage company PepsiCo designed to improve the treatment for children with TB. Many of today’s TB treatments are very bitter or unpleasant in taste, which when compounded with the long duration of treatment for TB, can lead to low tolerance and poor compliance – especially among children.
28 October 2016 | TB Alliance
Even before the costs of getting diagnosed, picked up in some high-tuberculosis incidence countries by patients themselves, and even before treatment brings its own costs, the financial toll of tuberculosis has already begun, a representative of the World Health Organization said today.
26 October 2016 | Science Speaks
MU researchers, working with scientists in Africa, discovered that a widely used African botanical supplement called Sutherlandia — traditionally taken to prevent or treat symptoms of infections — may actually disrupt the effectiveness of a common anti-tuberculosis drug, isoniazid.
11 October 2016 | Kansas City Star
TB medicines specially adapted for children have been available since 2015, as a result of the UNITAID-funded STEP-TB project. In 2013 UNITAID committed 16.72 million dollars towards the implementation of the STEP-TB project, which brought together TB Alliance, and other partners to develop the first formulations of TB medicines that meets dosage guidelines set by the World Health Organization (WHO) in 2010.
27 September 2016 | UNITAID
Aimed at the pharmaceutical industry, research institutions, product development partnerships and donors, the new profiles seek to guide the drug/regimen development process, enabling important drug and regimen features to respond to the needs of end-users, care providers and policymakers.
08 September 2016 | World Health Organization
The findings show that TB bacteria may persist in the lungs even after patients have finished treatment and are free of clinical symptoms. Although it is unclear how this might affect the risk of disease relapse, the study results underscore the need for new diagnostic methods and improved TB treatment strategies, according to the researchers.
07 September 2016 | National Institute of Allergy and Infectious Diseases
Tuberculosis is a leading killer of people with HIV, and providing therapy for both illnesses simultaneously saves lives - according to new guidelines on the treatment of drug-susceptible TB developed jointly by the American Thoracic Society, Centers for Disease Control and Prevention and Infectious Diseases Society of America. Treatment of TB in the presence of HIV infection is one of several special situations addressed in the new guidelines.
15 August 2016 | Eurekalert Inf Dis
Patients diagnosed with tuberculosis as well as HIV do better in combating tuberculosis with an intensified daily regimen rather than intermittent therapy that delivers less medicine, researchers reported here.
22 July 2016 | MedPage Today HIV/AIDS